Molecular Subtype
Chronic Myeloid Leukemia, BCR-ABL1 Positive
CI-CAN-00002365CMLExplore in graph →
Hematologic102 active trials3 approved drugs320 evidence items
- NCIt
- C3174
- OncoTree
- CMLBCRABL1
- DOID
- 0081088
- DOID
- 8552
Loading cancer entity…
Molecular Subtype
CI-CAN-00002365CMLExplore in graph →
Clinical trials
649 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (104)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06680661 | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis | suspended | Phase 2 | 20 | Leland MethenyOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05400122 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | suspended | Phase 1 | 12 | David WaldOTHER | 1 | Jul 14, 2026 | clinicaltrials |
Showing 1–2 of 2 studies
Data updated 19 days agoSource updated Sep 10, 2026source: clinicaltrials